CRISPR/Cas12a-mediated ultrasensitive and on-site monkeypox viral testing

Furong Zhao\textsuperscript{a, 1}, Pei Wang\textsuperscript{a,b, 1}, Haoxuan Wang\textsuperscript{a, 1}, Sirui Liu\textsuperscript{a}, Muhammad Sohail\textsuperscript{a},

Xing Zhang\textsuperscript{a}, Bingzhi Li\textsuperscript{a, *}, He Huang\textsuperscript{a, *}

\textsuperscript{a} School of Food Science and Pharmaceutical Engineering, Nanjing Normal University

\textsuperscript{b} School of Life Sciences, Nanjing Normal University, Nanjing 210023, China

\textsuperscript{1} Equal contributions:

F.Z, P.W, and H.W. contributed equally to this work.

\textsuperscript{*} Corresponding Author:

Bingzhi Li (bingzhili@njnu.edu.cn)

He Huang (huangh@njnu.edu.cn)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

The unexpected transmission of monkeypox virus (MPXV) from Central and West Africa to previously non-endemic locations is triggering a global panic. The ultrasensitive, rapid, and specific detection of MPXV is crucial for controlling its spreading, while such technology has rarely been reported. Herein, we proposed an MPXV assay combining recombinase-aided amplification (RAA) and CRISPR/Cas12a for the first time. This assay targeted MPXV F3L gene and yielded a low detection limit (LOD) of $10^1$ copies/μL. Deriving from the high specificity nature of RAA and CRISPR/Cas12a, through rational optimizations of probes and conditions, this assay showed high selectivity that could distinguish MPXV from other orthopox viruses and current high-profile viruses. To facilitate on-site screening of potential MPXV carriers, a kit integrating lateral flow strips was developed, enabling naked-eye MPXV detection with a LOD of $10^4$ copies/μL. Our RAA-Cas12a-MPXV assay was able to detect MPXV without the need for sophisticated operation and expensive equipment. We envision that this RAA-Cas12a-MPXV assay can be deployed in emerging viral outbreaks for on-site surveillance of MPXV.

Keywords: CRISPR; Cas12a; Monkeypox; Nucleic acid testing; Point-of-care testing
Introduction

As a member of the genus orthopoxvirus (OPXV) in the family Poxviridae, monkeypox virus (MPXV) is a double-stranded DNA (dsDNA) virus firstly isolated in 1958.\textsuperscript{1-3} Monkeypox was not recognized as a zoonotic disease until the first human case discovered in a 9-month-old boy in Zaire (now the Democratic Republic of the Congo) in 1970.\textsuperscript{4-6} Animal-to-human transmission of MPXV can occur via humans’ close contact with infected animals while human-to-human transmission includes contact with bodily fluids, respiratory droplets, and lesion materials of the infected individual, sexual transmission, and maternal-infant transmission.\textsuperscript{7, 8} Since the first human case, monkeypox has become predominantly endemic in Central and West Africa, for example, Nigeria experienced a large monkeypox outbreak in 2017, with relevant cases continuously emerging.\textsuperscript{9-11} It was not until 2003 that the first case occurred in the United States, mainly due to the importation of infected pet prairie dogs from Ghana. Since 2018, monkeypox has also been reported in tourists from Nigeria to other non-endemic countries, involving Israel,\textsuperscript{12} the United Kingdom,\textsuperscript{13, 14} Singapore,\textsuperscript{15} the United States of America,\textsuperscript{16, 17} and others.\textsuperscript{18} Disturbingly, the World Health Organization (WHO) has collected a total of 71,237 laboratory-confirmed cases and 1,097 probable cases from 107 infected member countries since 1 January 2022, and declared this outbreak a public health emergency of international concern.\textsuperscript{19} It has become a new reality that human monkeypox is no longer a rare zoonotic disease, which deserves more public health attention.\textsuperscript{20} Thus, the detection of monkeypox matters even more in the current post-COVID, more vigilant world.\textsuperscript{21}
Currently, the MPXV testing relies on methods including polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), loop-mediated isothermal amplification (LAMP), and microarray. PCR, recognized as the gold standard for the diagnosis of various diseases including monkeypox, displays high accuracy and sensitivity, yet its application in low-resource areas is limited due to its requirements for expensive equipment and skilled operators. ELISA may fail in providing MPXV-specific analysis for the serologically cross-reactive characteristic of OPXV and lead to false positive results for recent or remote vaccination. LAMP is free from precise thermo-cycling, but it suffers from complicated primer design, false positives, and poor quantitative performance. Besides, the microarray method has been developed for the detection and discrimination of OPXV species; however, its practicality and accessibility is limited deriving from high cost and long detection time. Therefore, low-cost, ultrasensitive, and rapid methods that can facilitate on-site and facile MPXV detection have remained elusive.

CRISPR/Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated protein) discovered in the adaptive immune system of prokaryotes, was initially proposed as a revolutionary gene editing technology and later expanded to the fields of molecular diagnosis and biosensing. CRISPR/Cas12a system that integrates biorecognition (Cas12a crRNA binding to the target) with signal transduction (activated Cas12a indiscriminately cleaving any surrounding single-stranded DNA reporters) has participated in the detection of
various viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), African swine fever virus (ASFV), human immunodeficiency virus (HIV), displaying obvious advantages of mild conditions, operational simplicity, great sensitivity, and potent signal amplification. Currently, the CRISPR/Cas12a-based MPXV assay has not been systematically reported. According to the best of our acknowledge, there is only one short letter discussed the possibility of implementing CRISPR technology in MPXV detection, while details on pre-amplification, probe screening, analytical performance, and point-of-care testing (POCT) have not been included.

Herein, we proposed an ultrasensitive and rapid MPXV assay that integrates recombinase-aided amplification (RAA) with CRISPR/Cas12a (the RAA-Cas12a-MPXV assay) for the first time. After RAA pre-amplification of DNA templates (containing MPXV F3L gene), CRISPR/Cas12a-based amplicon recognition, and rapid cleavage of reporters, ultrasensitive detection of MPXV down to $10^1$ copies/$\mu$L via fluorescence readout was accomplished, which is 1000-fold more sensitive than PCR. For MPXV POCT, we chose lateral flow strip technology as the reliable interpretation of the assay and achieved the detection limit of $10^3$ copies/$\mu$L. Our RAA-Cas12a-MPXV assay has the potential to detect MPXV with excellent sensitivity, and selectivity with the aid of basic heaters, providing a rapid, convenient, visual method for on-site screening in low-resource regions.
Results and Discussion

Principle and verification of RAA-Cas12a-MPXV Assay

The principle of our RAA-Cas12a-MPXV assay is illustrated in Scheme 1. It consists of three steps: RAA amplification, CRISPR/Cas12a cleavage, and signal output. In the first step, RAA selecting the DNA template, the conserved region of MPXV-specific $F3L$ gene,\textsuperscript{41-43} as the target sequence, produces numerous amplicons enhanced the sensitivity of the assay. In the second step, crRNA-specific recognition and binding of amplicons activate the \textit{trans}-cleavage activity of Cas12a, resulting in a large number of ssDNA reporters cleaved. Depending on different reporters, the third step presents two modes of signal output, fluorescence assay for FQ reporters (modified with 6-FAM at the 5’ end and BHQ1 at the 3’ end) and lateral flow strip assay for FB reporters (modified with 6-FAM at the 5’ end and biotin at the 3’ end), improving the suitability and usability of our RAA-Cas12a-MPXV assay. The departure of fluorophores of FQ reporters from quenchers enables fluorescence assay using a fluorescence reader. In lateral flow strip assay, biotin of FB reporters is captured by streptavidin at the first line on the strip (control), while the FAM/anti-FAM antibody/AuNP complex migrates toward the second line (test) and bind to anti-FAM. The result is visible within 5 min after sample addition at room temperature, and the appearance of red color at the test band is considered positive.
Scheme 1. The principle of RAA-Cas12a-MPXV assay proposed in this research.

RAA for DNA template amplification; CRISPR/Cas12a system for reporter cleavage; fluorescence assay and lateral flow strip assay for detection signal output.

To assess the feasibility of our RAA-Cas12a-MPXV assay, we compared fluorescence results with or without DNA templates, and RAA product. As shown in Figure 1A, the control group without DNA templates brought no significant fluorescence change (NTC, blue line), indicating that no RAA amplicon was generated for recognition by subsequent CRISPR/Cas12a in the absence of DNA templates. The blank control without RAA product also showed no fluorescent signal, demonstrating that CRISPR/Cas12a system does not cleave reporters without amplicons (NRP, black line). Accordingly, we excluded the possibility of false positive results due to contamination and non-specific amplification during RAA, as well as non-specific cleavage of reporters during CRISPR/Cas12a. In contrast, in the presence of DNA templates, RAA replicated numerous amplicons for crRNA recognition and Cas12a activation, resulting in an intense fluorescence signal (red...
The results obtained by the fluorescence reader were consistent with the fluorescence spectroscopy (Figure 1B). Moreover, the fluorescence signal could be observed by the naked eyes under ultraviolet (UV) light (Figure 1B, inset).

**Figure 1.** Verification of RAA-Cas12a-MPXV testing strategy. (a) Fluorescence spectra of feasibility verification. (b) Fluorescence intensity of feasibility verification. The inset was photographed by a smartphone under UV light. RAA was carried out under 42 °C for 30 min using F2 and R2, then 1 μL RAA product was added to 20 μL CRISPR/Cas12a reaction (50 nM Cas12a, 50 nM CrRNA, 1 μM FQ reporter, 1 × Cas Buffer). NRP, no RAA product; NTC, no template control; P, positive.

**Design and screening of RAA primers and Cas12a crRNA**

RAA primers are the main factors affecting RAA amplification efficiency. To obtain higher sensitivity and selectivity, three pairs of primers binding at different sites of the MPXV-specific *F3L* gene were designed (Figure 2a, Table S1). Agarose gel electrophoresis (AGE) and the RAA-Cas12a-MPXV fluorescence assay were performed to screen the optimal primers for further experiments. The result of AGE suggested that amongst the three pairs of RAA primers, only the third pair (F2+R2)
achieved the brightest specific amplification band while having no non-specific amplification band (Figure 2b). The fluorescence assay further confirmed F2 and R2 as the most efficient primers, with the lowest fluorescence in NTC and the highest fluorescence in P (Figure 2c).

**Figure 2.** Screening optimal primers for RAA. (a) The binding sites of designed primers on the DNA template. (b) AGE of RAA product. M, DNA marker; lane NTC1 and P1, RAA products using F1.1 and R1; lane NTC2 and P2, RAA products using F1.2 and R1; lane NTC3 and P3, RAA products using F2 and R2. (c) Fluorescence intensity of RAA-CRISPR/Cas12a assay. NTC, no template control; P, positive.

Cas12a crRNA plays a central role in amplicon recognition and Cas12a activation, thus, to obtain the optimized crRNA that can potently activate Cas12a, we designed three crRNAs with the same length, while targeting to different sites on the RAA amplicon (Figure 3a). All of the crRNAs we designed activated Cas12a which
subsequently cis-cleaved amplicons (no bands in the insert of Figure 3b) and trans-cleaved FQ reporters (rising fluorescence in Figure 3b), while crRNA2 was the best candidate for its highest fluorescence intensity. With crRNA2-activating CRISPR/Cas12a, we observed a considerable fluorescence difference between the negative group and the positive group (Figure 3c). Consequently, we selected crRNA2 for the following study.

**Figure 3.** Screening an optimal crRNA for CRISPR/Cas12a. (a) The binding sites of designed crRNAs on the DNA template (Green, crRNA binding sites; purple, PAM motifs). (b) Fluorescence intensity of CRISPR/Cas12a assay using different crRNAs. NC, no crRNA. The inset was an agarose gel image corresponding to different groups. Lane NC, CRISPR/Cas12a reaction products with no crRNA; lane crRNA1, CRISPR/Cas12a reaction products using crRNA1; lane crRNA2, CRISPR/Cas12a reaction products using crRNA2; lane crRNA3, CRISPR/Cas12a reaction products using crRNA3. (c) Fluorescence intensity of CRISPR/Cas12a assay using the
optimum crRNA2. Negative, without templates; positive, with templates.

Optimization of the assay conditions

To obtain optimal analytical performance of our RAA-Cas12a-MPXV assay, several critical experimental conditions during RAA amplification and the CRISPR/Cas12a system were optimized. We first optimized the temperature and reaction time of RAA based on the optimal primers (F2 and R2). The band of 30-min RAA was significantly brighter than that of other amplification times (Figure 4a), and the fluorescence result reconfirmed 30 min as the ideal RAA reaction time (Figure S1).

Likewise, we chose 42°C as the optimal temperature for RAA by combining the results of electrophoresis and fluorescence assay (Figure 4b, Figure S1).

After the determination of RAA amplification conditions (42°C, 30 min), we further optimized the CRISPR/Cas12a system with crRNA2. We first investigated the cleavage ability of Cas12a at different reaction times. The fluorescence intensity spiked rapidly from the onset of the reaction to 40 min, and the cleavage efficiency reached its maximum at 40 min, after which the fluorescence slowly increased (Figure 4c), thus, we chose 40 min as the best CRISPR reaction time. Furthermore, we explored the effects of Cas12a:crRNA on the ultimate fluorescence intensity and found that 1:1 was the optimal ratio (Figure 4d).
Figure 4. Optimization of the assay conditions. (a) The agarose gel image of RAA amplification products under different reaction times (15 min, 20 min, 25 min, 30 min, 35 min). (b) The agarose gel image of RAA amplification products under different temperatures (42 °C, 39 °C, 37 °C, 35 °C, 32 °C). NTC, no template control. (c) Fluorescence intensity of CRISPR/Cas12a assay under different reaction times (10 min, 20 min, 30 min, 40 min, 50 min, 60 min, 70 min). Cleavage efficiency = fluorescence intensity/CRISPR time. (d) Fluorescence intensity of CRISPR/Cas12a assay using different ratios of Cas12a and crRNA (10:1, 5:1, 1:1, 1:5, 1:10). NC, no crRNA.

Performances of the proposed RAA-Cas12a-MPXV fluorescence assay

As shown in Figure 5a, our proposed RAA-Cas12a-MPXV fluorescence assay has the merits of easy operation and rapid testing. To evaluate the sensitivity of the
fluorescence assay, DNA templates at serial dilution concentrations in the range of $10^0$ to $10^{10}$ copies/µL were subjected to RAA amplification, and then a 1 µL amplification product was taken for the CRISPR/Cas12a reaction. The resulting fluorescence intensity in Figure 5a exhibited that compared to the control group without the DNA template and RAA product, the difference initiated in the group of $10^1$ copies/µL, and gradually widened in the following groups, hence the limit of detection (LOD) of the RAA-Cas12a-MPXV fluorescence assay was $10^1$ copies/µL. Additionally, we achieved the LOD of $10^2$ copies/µL via naked-eye observation under UV light (Figure 5b, insert). We also evaluated the sensitivity of the PCR-Cas12a-MPXV fluorescence assay (detailed in Supporting Information). In comparison with the PCR-Cas12a-MPXV fluorescence assay, the LOD of which was $10^4$ copies/µL (Figure S2), the RAA-Cas12a-MPXV fluorescence assay we established achieved 1000-fold lower LOD, performing outstanding sensitivity. The higher sensitivity of RAA-based assay is ascribed to the higher amplification efficiency of RAA and the better compatibility of RAA to CRISPR.44-46

The selectivity of our RAA-Cas12a-MPXV fluorescence assay was next assessed by comparing the fluorescence intensity produced by MPXV with that produced by other viruses: cowpox virus (CPXV), variola virus (VARV), ASFV, and Toxoplasma Gondii virus (TOXV), SARS-CoV-2. Both fluorescence values and naked-eye observation demonstrated that only the MPXV group induced enhanced fluorescence while other orthopox viruses (CPXV and VARV), and current high-profile viruses (ASFV, TOXV, SARS-CoV-2) showed no fluorescence changes (Figure 5c). These
results confirmed the superior selectivity of our strategy toward MPXV, which is derived from the outstanding specificity of RAA amplification and Cas12a recognition.47-49

Figure 5. Performances of the RAA-Cas12a-MPXV fluorescence assay. (a) Flowchart of the fluorescence assay. (b) Fluorescence intensity responding to a serial 10-fold dilution (10^{10-0} copies/μL) of DNA templates in the sensitivity evaluation. The inset was photographed by a smartphone under UV light. Copy numbers and serial dilution values that are significantly different from each other are labeled with different lowercase letters above the error bars (p < 0.05). (c) Fluorescence intensity responding to MPXV, CPXV, VARV, ASFV, TOXV, and SARA-CoV-2 in the selectivity evaluation. The inset was photographed by a smartphone under UV light. NRP, no RAA product; NTC, no template control.
To enable POCT, we designed the FB reporter as a substitute for the FQ reporter of the fluorescence assay and established the RAA-Cas12a-MPXV lateral flow strip assay (Figure 6a). Upon the addition of the reaction solution containing both intact FB reporters and cracked FAMs and biotins at the sample pad, the anti-FAM antibody/AuNP complexes quickly bound to the isolated FAMs as well as the intact FB reporters as the sample migrated forward. Subsequently, the streptavidin, which was immobilized at the control band, captured the cracked biotins and the FB reporter/anti-FAM antibody/AuNP complexes, so that the control band appeared red owing to the aggregation of AuNPs. The rest isolated FAM/anti-FAM antibody/AuNP complexes migrated toward the test band and were captured by the FAM antibodies, appearing red. Once there were enough amplicons to activate Cas12a to cleave all FB reporters at maximum capacity, the color change would only appear at the test band as a result. In brief, the color change appearing at the test band only or both the control band and the test band indicated a positive result. In the negative group, the absence of the DNA templates led to no amplicons for Cas12a activation and reporters cleavage, consequently, the red color appeared only at the control band.

In the sensitivity assessment, with the increasing number of DNA templates, amplicons for crRNA recognition and Cas12a activation incrementally grew via RAA, eventually leading to a growing number of FB reporters being cleaved into FAM and biotin, allowing the result that the color became darker at the test band and became lighter at the control band presented on the lateral flow strips. Through naked-eye observation, our RAA-Cas12a-MPXV lateral flow strip assay achieved the LOD of
10^4 copies/μL (Figure 6b). Besides, this lateral flow strip assay showed great selectivity, as demonstrated by the cross-reactivity test with other orthopox viruses and current high-profile viruses (Figure 6c).

**Figure 6.** Performances of the RAA-Cas12a-MPXV lateral flow strip assay. (a) Flowchart of the lateral flow strip assay. (b) Lateral flow strip results responding to a serial 10-fold dilution (10^{10-0} copies/μL) of DNA templates in the sensitivity evaluation. (c) Lateral flow strip results responding to MPXV, CPXV, VARV, ASFV, TOXV, and SARA-CoV-2 in the selectivity evaluation. NTC, no template control.
Conclusions

In this work, we established an RAA-Cas12a-MPXV assay for ultrasensitive, facile, and rapid detection of MPXV by integrating RAA amplification with CRISPR/Cas12a system and outputting the detection signal in the form of fluorescence or lateral flow strip. Compared to current methods reported for detecting MPXV, our RAA-Cas12a-MPXV assay possessed its notable strengths: (1) our assay was carried out at a gentle temperature throughout, getting rid of the restraints of thermal cycling processes and expensive instruments; (2) compared to the conventional PCR with the LOD of $10^4$ copies/μL, our assay exhibited a significantly improved detection limit of $10^1$ copies/μL in the fluorescence assay, 1000-fold more sensitive than PCR. Meanwhile, visualized detection was realized with the LOD of $10^2$ copies/μL via UV light, and $10^4$ copies/μL via lateral flow strip; (3) combining the lateral flow strip enabled us to perform on-site detection via naked eyes within 5 min at room temperature with no need for any lab equipment, revealing the POCT potential for screening MPXV in low-equipment scenario. Overall, the RAA-Cas12a-MPXV assay is a promising method for MPXV detection with outstanding sensitivity, selectivity, and portability.
Experimental section

Materials and Reagents

The oligonucleotides used in this study were synthesized and purified by Sangon Biotech (Shanghai, China) and listed in Table S1. The monkeypox virus F3L plasmid was purchased from Sangon Biotech. The RAA nucleic acid amplification kit (S001ZC) was purchased from ZC Bioscience (Hangzhou, China). The 2 × Taq Master Mix (P111) for PCR and the fastpure gel DNA extraction mini kit (DC301) were provided from Vazyme Biotech (Nanjing, China). The Cas12a nuclease was expressed and purified by our laboratory, details were provided in the supporting information. Reagents in the 10 × Cas Buffer (500 mM NaCl, 100 mM Tris-HCl, 100 mM MgCl2, 1 mg/mL BSA, pH 7.9) were purchased from Aladdin (Shanghai, China). The lateral flow strip was purchased from IVD Biotech Service Center (Shanghai, China).

Primers and crRNAs Design

The MPXV F3L gene sequence in this study was derived from German strain MPXV-BY-IMB25241 (GenBank: ON568298) in May 2022 and American strain MPXV-USA-2022-MA001 (GenBank: ON563414) during the same period, the difference of which from Zaire strain Zaire-96-l-16 (NCBI Gene ID: 928998) was a partial site mutation. Referring to the previously reported PCR primers for Zaire strains with some changes, we designed three pairs of RAA primers and screened out the best primers in the follow-up. Cas12a crRNA consisted of a repeat sequence and a amplicon-specific sequence. We designed three 19-nt crRNAs without the PAM.
motif (TTTN), while the PAM motif appeared at the 5’ end of the non-complementary DNA sequence being targeted.

**Plasmid Construction and Amplification**

The gene sequences of CPXV, VARV, ASFV, and *Toxoplasma Gondii* virus (TOXV) were retrieved from GenBank under accession number X75158, AY552594, MN809121 and AF146527, then cloned into PUC57 vectors (Sangon, China) to create the recombinant plasmids. After transformation into *E. coli* DH5α and expansion overnight, the recombinant plasmids were extracted using AxyPrep plasmid DNA mini kit (AP-MN-P-50) purchased from Axygen Biotech (Hangzhou, China). The concentrations of extracted plasmids were determined with NanoDrop 2000 (Thermo Fisher, United States).

**Recombinase-Aided Amplification Reaction**

RAA reaction was performed with the RAA nucleic acid amplification kit, following the manufacturer’s instructions. Explicitly, the reaction powder was dissolved with a mixture containing 5 µL A Buffer (provided in the kit), 0.4 µL each of 10 µM forward primer and reverse primer, and 2.7 µL ddH2O. Then, 1µL DNA template and 0.5µL B Buffer (provided in the kit) were added into the reaction tube and mixed gently, followed by incubation at 42 °C for 30 min. The DNA template was replaced by ddH2O in no template control (NTC) reaction. RAA products were verified by 3 % AGE after purification by the fastpure gel DNA extraction mini kit. The optimum primers for RAA were screened under the observation of the brightness of the specific bands and the absence of non-specific bands after electrophoresis.
RAA-Cas12a-MPXV Fluorescence Assay

The RAA-Cas12a-MPXV fluorescence assay was performed in a 20 μL system containing 1 × Cas Buffer, 50 nM crRNA, 50 nM Cas12a, 1 μM FQ reporter, and 1 μL RAA product. Cas12a and crRNA were pre-conjugated in Cas Buffer at 37 °C for 10 min to facilitate cleavage performance of Cas12a. After the addition of FQ and RAA product, the CRISPR reaction was incubated at 37 °C for 40 min and observed under the FAM channel of the BioTek Synergy H1M microplate reader (Bio-Tek, United States). In no RAA product (NRP) reaction, ddH₂O was in place of the RAA product.

RAA-Cas12a-MPXV Lateral Flow Strip Assay

The reaction system of the RAA-Cas12a-MPXV lateral flow strip assay was similar to the fluorescence assay above, except for the replacement of the FQ with the FB reporter. After incubation at 37 °C for 40 min, sterile ddH₂O was added to make up the reaction system to 50 μL for the insertion of the lateral flow strip. The result was visualized after 5 min incubation at room temperature. The color appeared only at the control band, indicating a negative result, and the color appeared at the test band or both bands, indicating a positive result.

Statistical Analysis

Software OriginPro 2021 (OriginLab, Northampton, MA) was used for statistical analyses and graphs. Data were shown as the average ± standard deviation (n = 3). Error bars represent the standard deviation from three independent experiments.
Acknowledgments

This work was supported by grants from the Natural Science Foundation of Jiangsu Province (No. BK20200718 to B.Li), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (20KJB350010 to B.Li), Jiangsu Innovation and Entrepreneurship Doctoral Program to X.Zhang, and Jiangsu Specially-Appointed Professor Project to X.Zhang.

Conflict of Interest Disclosure

The authors declare no competing financial interest.
References


(9) Reed, K. D.; Melski, J. W.; Graham, M. B.; Regnery, R. L.; Sotir, M. J.; Wegner, M. V.; Kazmierczak, J. J.; Stratman, E. J.; Li, Y.; Fairley, J. A.; et al. The detection of...


https://worldhealthorg.shinyapps.io/mpx_global/.


inform the recent monkeypox outbreak. *Public Health Pract (Oxf)* **2022**, 4, 100315.


(28) Ryabinin, V. A.; Shundrin, L. A.; Kostina, E. B.; Laassri, M.; Chizhikov, V.;


(35) Xie, S.; Qin, C.; Zhao, F.; Shang, Z.; Wang, P.; Sohail, M.; Zhang, X.; Li, B. A DNA-Cu nanocluster and exonuclease I integrated label-free reporting system for


(48) Li, F.; Ye, Q.; Chen, M.; Xiang, X.; Zhang, J.; Pang, R.; Xue, L.; Wang, J.; Gu, Q.; Lei, T.; et al. Cas12aFDet: A CRISPR/Cas12a-based fluorescence platform for


For TOC only